Type I interferon (IFN) is used for the treatment of chronic hepatitis C virus (HCV) infection. Despite advances in antiviral therapy, a large proportion of patients remain infected following current therapies. Through a genome-wide scan, we found two variants (rs8099917 and rs12979860) in the IL-28B locus that affect the outcome of PEG-IFN and ribavirin combination therapy, consistent with recent studies (P56.52¾10 -8 ; odds ratio 2.46 and P58.63¾10 -8 , odds ratio 2.40, respectively). Significant associations were also observed in the case of IFN monotherapy for HCV genotypes 1b and 2a. With rs8099917, HCV genotype 1b patients had a significantly lower frequency of the favourable genotype (86.6 %) compared with healthy controls (91.7 %), and HCV genotype 2a patients had an intermediate frequency (89.9 %). Similar results were found for rs12979860. Fine-mapping analysis revealed that rs8099917 had the strongest association with treatment outcome and 14 others, including four novel single nucleotide polymorphisms, had comparable associations. Haplotype analysis revealed that none of the haplotypes showed stronger association than any single marker. Early non-responders who could not achieve 2 log viral decline during the first 12 weeks of treatment had higher odds ratios for these two variants. The favourable allele of rs8099917 is also associated with initial viral decline at 2 and 4 weeks following the start of therapy. Multivariate analysis of PEG-IFN and ribavirintreated patients showed that rs8099917 genotype, viral load, fibrosis and age were significant predictors of response to therapy. Common variation at the IL-28B locus is predictive of various IFN-based therapies for HCV independent of regimen or HCV genotype.
INTRODUCTION
Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular carcinoma (Barrera et al., 1995; Welzel et al., 2009) . The only drug that can currently lead to the eradication of HCV is interferon (IFN) . Sustained viral response (SVR), defined as HCV RNA negative 24 weeks after cessation of therapy, can be achieved by the current treatment regimen of pegylatedinterferon (PEG-IFN) combined with ribavirin, but this can only be attained in less than 50 % of patients infected with genotype 1 HCV, in contrast to the higher eradication rates for other HCV subtypes (Hadziyannis et al., 2004; Manns et al., 2001) . Both viral [e.g. HCV genotype, amino acid substitutions in the NS5A (Enomoto et al., 1996) and core region (Akuta et al., 2007) ] and host factors [young age (Manns et al., 2001) , body mass index (Bressler et al., 2003) and insulin resistance (Romero-Gó mez et al., 2005) ] influence the outcome of IFN therapy. Viral load and the stage of liver fibrosis, which vary among patients even when they have been infected by the same donor (Casiraghi et al., 2004; Kenny-Walsh & Irish Hepatology Research Group, 1999) , have also been reported to influence the outcome of IFN therapy (Tsubota et al., 1994) . Different disease outcomes and effects of IFN therapy may also partly depend on host genetic factors, and different responses among ethnic groups have been reported (Conjeevaram et al., 2006; Welzel et al., 2009) . To date, polymorphisms in myxovirus resistance protein A (Hijikata et al., 2000; Knapp et al., 2003) , IFN-a-receptor 1 (Matsuyama et al., 2003) , osteopontin (Naito et al., 2005) and mitogenactivated protein kinase-activated protein kinase 3 (Tsukada et al., 2009) have been reported to be associated with IFN response by candidate gene approach. However, most of these studies were limited by their relatively small sample sizes and lack of validation. Thus, the host genetic factors that influence IFN responsiveness in HCV-infected patients have not been fully explored. Recently, Ge et al. reported an association between variation at the IL-28B locus and the outcome of PEG-IFN and ribavirin therapy among genotype 1b-infected European Americans, African Americans and Hispanics . The association was also independently reported by two other research groups (Suppiah et al., 2009; Tanaka et al., 2009) .
In this report, we analysed 2028 Japanese and 73 Taiwanese patients treated with IFN for HCV infection and compared them with 282 Japanese healthy control subjects. Our results not only replicate recent findings regarding the predictive effect of IL-28B variation on the outcome of PEG-IFN and ribavirin therapy against HCV genotype 1b, but also showed similar association in HCV patients with genotype 1b and genotype 2a under various therapeutic regimes. We also provide important resequencing data for the IL-28B locus.
RESULTS
IL-28 locus single nucleotide polymorphism (SNP) genotypes and the effect of therapy SNPs (510 537) on the Illumina chips passed qualitycontrol filters. During the quality control check, one subject from each of the 11 close relative pairs was removed from the association analysis according to PI_HAT value. Subsequent principal component analysis identified no outliers from the JPT/CHB clusters. Finally, 304 sustained responders (SRs) and 279 non-responders (NRs) treated with PEG-IFN plus ribavirin were retained and tested for association with the outcome of IFN therapy. Since the genomic control inflation factor was 0.945, indicating that population substructure effects were negligible, we did not correct for genomic control in the genome-wide association analysis. Two SNPs (rs8099917 and rs12979860) located upstream of IL-28B on chromosome 19 showed strong associations with the response to IFN therapy (uncorrected P52.7610
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, 3.9610 29 , respectively). We conclude that these top two SNPs are in strong linkage disequilibrium and that we are detecting essentially the same signal (r 2 50.95). Thus, detailed results of only rs8099917 are shown (Table 1 ). The calculated odds ratio (OR) of the most significant SNP (rs8099917) for IFN response was 2.7 (95 % CI, 1.9-3.8) using the allele model. There was no significant association between SNPs and the treatment outcome in any other region.
As shown in Table 1 , the other sets, including genotype 1b-as well as genotype 2a-infected patients, also showed statistically significant associations. A combined analysis of genotype 1b or genotype 2a sets also provided strong evidence of an association between treatment outcome and polymorphism at the IL-28B locus.
Genotype frequencies of the IL-28B polymorphisms in HCV genotypes 1b and 2a were compared with healthy control subjects ( IL-28B polymorphism and anti-HCV treatment outcome the LD block defined by the criteria of Gabriel et al. (2002) spans about 9 kb ( Fig. 1) , we carefully resequenced the 42 kb genomic region encompassing IL-28B and IL-28A loci using specific PCR primer sets and identified 71 common SNPs, including 22 novel SNPs with a minor allele frequency greater than 0.05.
Among the 71 common SNPs identified by resequencing, 34 that showed strong linkage disequilibrium (r 2 .0.64) with the landmark SNP (rs8099917) were further genotyped. rs8099917 was found to have the strongest association with treatment outcome, and 14 SNPs exhibited comparable associations, with P-values varying by less than one order of magnitude (Table 3 and Fig. 2 ). Haplotype analysis provided little additional information compared with the single marker analysis (data not shown). These results suggest that the association signal was driven by one of the identified SNPs.
Initial response for SNP rs8099917 in the IL-28B locus
Out of the patients infected with HCV genotype 1b who were treated with PEG-IFN and ribavirin combined therapy (Set-1 and Set-2), 443 patients with sufficient viral load data were analysed for viral kinetics. As shown in Fig.  2 (a, b), viral reduction in patients with rs8099917 TT is significantly greater than in those with rs8099917 TG or GG in both weeks 2 and 4. Baseline viral load in patients with rs8099917 TT were slightly but significantly higher than in those with rs8099917 TG or GG (Fig. 2c ).
Multivariate logistic analysis
Using the patients infected with HCV genotype 1b who were treated with PEG-IFN, a stepwise forward logistic regression analysis was performed to assess the impact of the IL-28B polymorphism. There were 217 patients with sufficient data for the analysis. We evaluated the following seven factors: age, sex, SNP rs8099917, fibrosis and baseline HCV-RNA level. We found that SNP rs8099917 is an independent factor associated with treatment outcome [OR, 0.27; 95 % confidence interval (CI), 0.12-0.87]. Other independent factors meeting the criteria for inclusion in the model are shown in Table 4 .
DISCUSSION
Various viral and host factors determine the outcome of IFN (+ribavirin) therapy (Akuta et al., 2007; Bressler et al., 2003; Casiraghi et al., 2004; Enomoto et al., 1996; KennyWalsh & Irish Hepatology Research Group, 1999; Manns et al., 2001; Romero-Gó mez et al., 2005) . Ethnic differences in the response to IFN therapy and in the rate of spontaneous clearance in chronic hepatitis C suggest the influence of genetic factors (Conjeevaram et al., 2006; Welzel et al., 2009 ). In the current study, we found that the influence of SNPs in the IL-28 locus was quite high. DOR of subjects infected with HCV having a favourable genotype relative to healthy control subjects.
Despite the fact that the total dose of PEG-IFN or IFN that was administered to each patient varied according to HCV genotype and viral titre based on the current standard regimen, the effect of the therapy in all patient cohorts showed significant association with the SNP genotypes. For replication analyses, we also found significant associations in the case of IFN monotherapy (Sets 3 and 4 in Recent studies have demonstrated that genotype frequency of IL-28B polymorphism varied considerably by ethnicity, which may explain much of the difference in response between different population groups and support the prediction that favourable alleles would be very much more IL-28B polymorphism and anti-HCV treatment outcome ) with the landmark SNP (rs8099917). DStatistical comparisons were performed using the Cochran-Armitage trend test. common in Asian populations than in other ethnic groups Thomas et al., 2009) . We genotyped rs8099917 and rs12979860 in 282 healthy Japanese volunteers, and the allele frequencies of these SNPs were found to be comparatively high (91 % for both), consistent with the relatively high SVR rates of East Asian populations. Sarrazin et al. (2010) reported that genotype 1-infected patients had a lower frequency of the favourable genotype of rs12979860 compared with healthy controls and that genotypes 2/3 patients had an intermediate frequency. This finding was confirmed in this study (Table 2) . On the other hand, they reported that the rs12979860 CC genotype, but not the rs8099917 and rs12980275 genotypes was significantly associated with SVR to (PEG-) IFN-a/ribavirin combination therapy in genotypes 2/3-infected patients. In this study, however, rs12979860 and rs8099917 were both strongly associated with SVR. This discrepancy may be due to differences among populations in the degree of linkage disequilibrium between these SNPs, and, in fact, these SNPs were in strong linkage disequilibrium in our healthy control subjects as well.
Of note in our study was that there was a significant difference in the initial viral reduction based on SNP genotype in patients treated with the PEG-IFN and ribavirin combination therapy. This finding holds important implications for the strategy of IFN-based anti-HCV therapy.
The mechanism by which polymorphisms within this locus influence the outcome of therapy has not been established. One of the polymorphisms in strong linkage disequilibrium with the two SNPs is a missense substitution within the IL-28B coding region. Recently, Urban et al. (2010) reported that there was no difference in antiviral potency between wild-type IL-28B and amino-acid substituted variant in vitro using an HCV replicon system. On the other hand, it has been reported that genetic variation in the IL-28B locus is associated with expression levels of IL-28B (plus IL-28A) IFN in peripheral blood mononuclear cells (Suppiah et Using a specific assay, Honda et al. (2010) and Urban et al. (2010) reported that hepatic IL-28B expression was not associated with IL-28B genotype in HCV-infected patients. Post-transcriptional regulation might be affected by the IL-28B variant, which could not be evaluated by the RT-PCR method, although further functional studies are needed to address this issue. IL-28A, IL-28B and IL-29 (IFN-l II, III and I, respectively) are recently identified IFNs (Kotenko et al., 2003; Sheppard et al., 2003) similar to type I IFNs in terms of biological activity and mechanism of action, but differ structurally and genetically (Maher et al., 2008) . The antiviral effects of IFN-l against hepatitis B virus and HCV have already been reported (Robek et al., 2005) . Furthermore, IFNs a and l act synergistically against HCV (Marcello et al., 2006; Pagliaccetti et al., 2008; Zhu et al., 2005) . Whether such synergy actually modulates the effect of IFN therapy against HCV in the liver requires further study. In this regard, recent studies have identified higher pre-treatment hepatic levels of IFN-stimulated genes in NRs than in responders (Chen et al., 2005; Feld et al., 2007; SarasinFilipowicz et al., 2008) . In addition, association between intrahepatic levels of ISG expression and IL-28B genotype have also been reported (Honda et al., 2010; Urban et al., 2010) . On the other hand, the IL-28B variant has recently been reported to be associated with treatment response following liver transplantation in patients infected with HCV (Charlton et al., 2011; Fukuhara et al., 2010) . These findings suggest that the IL-28B polymorphism may be associated with innate as well as adaptive immunity.
The OR for the effect of the PEG-IFN and ribavirin combination therapy associated with IL-28B polymorphisms in this study is much lower than the previous report that analysed a similar effect in Japanese patients (Tanaka et al., 2009) and is closer to those of Caucasian, Hispanic and African patients Suppiah et al., 2009 ). Tanaka et al.'s non-viral responder (NVR) criteria seem to be very constrained compared with those of other groups including ours. To evaluate possible effects of such limited criteria on ORs for treatment outcome, we divided our NRs into NVRs and transient viral responders (TVRs) by the use of Tanaka and colleagues criteria based on 2 log viral decline at 12 weeks. Among the Set-1 and Set-2 samples, 344 samples were available for this analysis (NVR, 58; TVR, 122; SVR, 164) . The ORs in the analyses for week 12 NVR versus SVR and for NVR versus VR (TVR plus SVR) are much greater than those based on our criteria and nearly comparable to those of Tanaka et al. (2009) (OR: 20.2, 17.2, respectively) . Accordingly, the extreme clinical phenotype of NRs, strongly dictated by early viral response, might account for the strongly associated OR values. Our viral kinetics study also supports this interpretation.
In conclusion, we have shown that polymorphisms located near the IL-28B locus (represented by rs8099917), reported to be associated with the outcome of PEG-IFN and ribavirin combined therapy, are also associated with that of IFN monotherapy and significantly affect early viral decline. Our resequencing and fine-mapping study identified 15 common genetic variants on the IL-28B locus that are associated with the outcome of IFN therapy for HCV infection. These findings would contribute to better targeting of PEG-IFN plus ribavirin therapy and increase overall treatment efficacy. Genotyping of IL-28B polymorphisms may be useful for predicting treatment outcome as well as estimating the optimal duration of PEG-IFN plus ribavirin combination therapy for viral eradication in HCV patients. Further study is needed to clarify the mechanism and molecular function of the IL-28B polymorphism to establish a more optimal, tailormade treatment regimen for each patient.
METHODS
Study populations. A total of 2112 patients with chronic HCV infection were included in the study who were treated either with PEG-IFN and ribavirin therapy or with IFN monotherapy at Toranomon Hospital Department of Hepatology, Hiroshima University Hospital, Hiroshima University-Affiliated Hospitals, and the National Taiwan University Hospital. All patients had abnormal levels of serum alanine transaminase for more than 6 months and were positive for both anti-HCV antibody and serum HCV RNA. All patients were negative for hepatitis B surface antigen, had no evidence of other liver diseases, and had not received immunosuppressive therapy before enrollment in the study. Table 5 lists the demographic features of the subjects. Patients were classified into the following two groups based on treatment outcome: SRs and NRs. SRs had no evidence of viraemia at 24 weeks after completion of IFN therapy, whereas NRs were still viraemic at this stage. For IFN monotherapy, patients were treated with 6 million units of IFN intramuscularly every day for 8 weeks, followed by the same dose twice a week for 16 weeks, with a total dose of 528 million units. In the PEG-IFN plus ribavirin combination therapy, subjects received weekly injections of PEG-IFN at 1.5 mg kg 21 body weight and oral administration of ribavirin for 48 weeks (for 24 weeks for Taiwanese patients). The amount of ribavirin was adjusted based on the subject's body weight (600 mg for ,60 kg, 800 mg for 60-80 kg and 1000 mg for .80 kg). Only patients with greater than 75 % compliance with prescribed doses of PEG-IFN and ribavirin were included in this study. For patients who underwent IFN-based therapies more than once, only parameters related to the most recent therapy were analysed. In addition, 282 healthy Japanese volunteers were genotyped for rs8099917 and rs12979860. All subjects in the present study received a detailed explanation, and all signed a written informed consent. This study was approved by the Ethical Committee of each participating medical centre and by the Ethical Committee at the SNP Research Center, the Institute of Physical and Chemical Research (RIKEN), Yokohama.
Genotyping. In the association study, we divided the Japanese patients who received PEG-IFN plus ribavirin into two independent groups based on the time of entry into the study (Set-1 and Set-2 in Table 5 ). For the GWAS stage, 594 Japanese patients with HCV genotype 1b treated with PEG-IFN plus ribavirin (315 SRs and 279 NRs) were initially genotyped using the Illumina HumanHap610-Quad Genotyping BeadChip (Set-1 in Table 5 ). The other samples were genotyped using the Invader assay, the TaqMan assay, or by direct sequencing as described previously (Ohnishi et al., 2001; Suzuki et al., 2003 Quality control criteria for the genome-wide study. For the genome-wide survey, we applied the following quality control criteria. Individual samples with genotype call rates less than 98 % and SNPs with call rates less than 99 % were removed, as were non-autosomal SNPs, minor alleles with a frequency less than 0.01, or SNPs deviating from the Hardy-Weinberg equilibrium (P,1610 26 ). Related individuals were detected by identity-by-state analysis performed with the PLINK software. One subject from each of the cryptically related pairs of individuals (PI_HAT .0.4) was excluded. We assessed IL-28B polymorphism and anti-HCV treatment outcome population stratification using the smartpca program from the EIGENSOFT package (http://genepath.med.harvard.edu/~reich/Software. htm) using genotypes for about 70 000 SNPs informative for the Japanese population according to the method described previously (Yamaguchi-Kabata et al., 2008) . Analysis was performed using the Set-1 samples and all four of the HapMap population datasets (CEU/YRI/ JPT/CHB). Outliers from JPT/CHB clusters were excluded from the association analysis. Genotype-based associations were tested with the Cochran-Armitage trend test. The genomic control method was applied to evaluate whether the inflation of false-positive rates, indicated by inflation factor l, was within an acceptable level.
Resequencing. Resequencing around the IL-28B locus was performed by direct sequencing of DNA from 48 unrelated Japanese HCV patients from the enrolled subjects. We used Phase II HapMap JPT genotype data and the HAPLOVIEW program to define an LD block.
HCV RNA level. The HCV RNA level was analysed at three time points: before IFN therapy, at the end of the second week and at the end of the fourth week, using an RT-PCR-based method (the original method, the high range method or the TaqMan RT-PCR test). The measurement ranges of these assays were 0.5-850 kilo (K) IU ml 21 , 5-5000 KIU ml 21 and 1.2-7.8 log IU, respectively. Set-1 and Set-2 patients with sufficient viral load data falling within the measurable range were included in the viral kinetics analysis.
Liver biopsy. Liver biopsy specimens were evaluated by a pathologist at each institution and were scored for the stage of liver fibrosis according to the classification of Desmet et al. (1994) . The patients were divided into two categories: mild fibrosis (F0-1) and severe fibrosis (F2-4).
Statistical analysis.
Genotype-based associations were tested using the allele model x 2 -test. SNP effects were also evaluated using the dominant, recessive and co-dominant models (using the CochranArmitage trend test). Combined analysis was performed following the Mantel-Haenszel method. Viral kinetics were assessed using the nonparametric Kruskal-Wallis test followed by the Steel-Dwass test. Multivariate logistic regression analysis with stepwise forward selection was performed with criteria of P,0.05 for inclusion and removal of variables using the StatFlex 5.0 software package (Artec Inc.).
